168 related articles for article (PubMed ID: 17685864)
1. Clinical trials of active cancer immunotherapy.
Nawrocki S; Mackiewicz A
Expert Opin Investig Drugs; 2007 Aug; 16(8):1137-41. PubMed ID: 17685864
[TBL] [Abstract][Full Text] [Related]
2. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
3. The role of vaccine therapy in the treatment of melanoma.
Lens M
Expert Opin Biol Ther; 2008 Mar; 8(3):315-23. PubMed ID: 18294102
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
5. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
6. Telomerase-based immunotherapy of cancer.
Carpenter EL; Vonderheide RH
Expert Opin Biol Ther; 2006 Oct; 6(10):1031-9. PubMed ID: 16989585
[TBL] [Abstract][Full Text] [Related]
7. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
8. Developing enabling technologies for the success of cancer immunotherapy.
Sznol M
Curr Opin Investig Drugs; 2004 Dec; 5(12):1239-42. PubMed ID: 15648943
[No Abstract] [Full Text] [Related]
9. Antigen-specific active immunotherapy for ovarian cancer.
Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.
Dalgleish AG
Vaccine; 2011 Nov; 29(47):8501-5. PubMed ID: 21933695
[TBL] [Abstract][Full Text] [Related]
11. Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions.
Franco A
Anticancer Agents Med Chem; 2008 Jan; 8(1):86-91. PubMed ID: 18220508
[TBL] [Abstract][Full Text] [Related]
12. Review: cancer immunotherapy by exosome-based vaccines.
Hao S; Moyana T; Xiang J
Cancer Biother Radiopharm; 2007 Oct; 22(5):692-703. PubMed ID: 17979572
[TBL] [Abstract][Full Text] [Related]
13. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic cancer vaccines: an emerging treatment option.
King SE
Clin J Oncol Nurs; 2004 Jun; 8(3):271-8. PubMed ID: 15208821
[TBL] [Abstract][Full Text] [Related]
15. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines.
Jaffee EM; Pardoll DM
Methods; 1997 Jun; 12(2):143-53. PubMed ID: 9184378
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: a critical review on clinical impact.
Bitton RJ
Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
[TBL] [Abstract][Full Text] [Related]
17. Advances in Therapeutic Cancer Vaccines.
Wong KK; Li WA; Mooney DJ; Dranoff G
Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
Chouaib S
Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055
[No Abstract] [Full Text] [Related]
19. Critical issues in cancer vaccine trial design.
Clifton GT; Kohrt HE; Peoples GE
Vaccine; 2015 Dec; 33(51):7386-7392. PubMed ID: 26392010
[TBL] [Abstract][Full Text] [Related]
20. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
